Why Alumis Inc.’s (ALMS) Stock Is Down 5.18%
As of Wednesday, September 23, Alumis Inc.’s ALMS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Commentary & Analysis
Why Alumis Inc.’s (ALMS) Stock Is Down 5.18%
As of Wednesday, September 16, Alumis Inc.’s ALMS share price has dipped by 5.18%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Alumis Inc.’s (ALMS) Stock Is Down 7.64%
As of Tuesday, September 15, Alumis Inc.’s ALMS share price has dipped by 7.64%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Why Alumis Inc.’s (ALMS) Stock Is Down 5.25%
As of Friday, September 11, Alumis Inc.’s ALMS share price has dipped by 5.25%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Alumis Inc.’s (ALMS) Stock Is Down 5.34%
As of Wednesday, September 09, Alumis Inc.’s ALMS share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
Financial Summary
| Share Statistics | ALMS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $849.1 | $492.0 | 44% |
|
| Shares Out (Mil) | 127.7 | 42.8 | 67% |
|
| Institutional Ownership | 99.2% | 82.8% | 86% |
|
| Float (Mil) | 91.3 | 44.4 | 59% |
|
| Beta | -0.67 | 0.71 | 2% |
|
| Avg Daily Volume (000s) | 2,167 | 376 | 83% |
|
| Price Change (52-week) |
47.8% | 55.3% | 83% |
|
| Growth | ALMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 3 | |
| Current EPS | ($0.750) | ($3.320) | ($2.873) | |
| Month Ago EPS | ($0.750) | ($3.260) | ($2.873) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.724) | ($2.902) | ($2.954) | |
| Year/Year Chg | (32.7%) | 16.0% | (24.9%) | |
| Financials | ALMS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $7 | $416 | 8% |
|
| Net Income (TTM) (Mil) | ($439) | ($11) | 3% |
|
| EPS (TTM) | ($3.801) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($351) | ($7) | 2% |
|
| Net Cash Flow (TTM) (Mil) | ($88) | $5 | 15% |
|
| Long-Term Debt (Q1) (Mil) | $32 | $6 | 35% |
|
| Enterprise Value (Q1) (Mil) | $2,810 | $494 | 53% |
|
| Valuation | ALMS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.86 | 2.15 | 50% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ALMS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 100.0% | 69.4% | 96% |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (74.9%) | (22.2%) | 8% |
|
| ROE | (93.6%) | (21.4%) | 10% |
|
| Liabilities to Assets | 19.3% | 32.8% | 12% |
|
| F-Score | 3 | 3 | 18% |
|
Alumis Inc. did not pass any screens on 10/13/2026.
